Ixico Share News (IXI)

Ixico profit, revenue down; expects return to medium, long-term growth

(Alliance News) - Ixico PLC on Wednesday said profit and revenue were down but it expects to return to growth over the medium and long term following recent client trial failures.

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Full-year revenue set to fall for Ixico

(Sharecast News) - Artificial intelligence (AI) data analytics company Ixico flagged full-year revenue of £8.6m in a trading update on Tuesday, down from £9.2m year-on-year.

IN BRIEF: Ixico shares down as annual revenue expected to drop

Ixico PLC - London-based neuroscience data analytics company - Expects revenue in year ended September 30 to be GBP8.6 million, down from GBP9.2 million the year before. Says year-on-year revenue fall reflects the "impact of the early cessation of client trials during the year". Order book amounts to GBP16.0 million at year-end, down from GBP18.8 million in prior year. "This reflects the signing of GBP12.6 million of new contracts during the year, offset by the delivery of GBP8.6 million revenue and GBP6.8 million contract value reductions due to the early client trial cessations and minor foreign exchange differences", Ixico notes.

IN BRIEF: Ixico shares rise as earnings to "comfortably" beat guidance

Ixico PLC - London-based neuroscience data analytics company - Says that trading in the second half of its financial year ending September 30 is "strong" and expects earnings before interest, tax, depreciation, and amortisation to "comfortably" exceed its previous guidance of GBP1.2 million. Does not give numbers for expected Ebitda. It was GBP1.7 million in financial year 2021. Adds that full-year revenue will be in line with market expectations.

AIM WINNERS & LOSERS: LoopUp shares up on "material" contract win

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Ixico to extend work on Huntington's disease trial

(Sharecast News) - Neuroimaging-focussed contract research organisation Ixico announced on Tuesday that an existing client has asked it to extend its breadth of services on their phase 1 and 2 trial into Huntington's disease.

IN BRIEF: Ixico extends Huntington's disease contract worth GBP800,000

Ixico PLC - London-based neuroscience data analytics company - Says it has extended a contract originally signed in April 2019. The existing client will use Ixico's services on its phase I/II trial into Huntington's disease. The contract extension is worth around GBP800,000, which Ixico expects to deliver across a four-year period.

IN BRIEF: Ixico interim profit falls; warns on cancelled client trials

Ixico PLC - London-based medical imaging company - Posts lower interim profit for the half year ended March 31. Pretax profit falls to GBP201,000 from GBP635,000 a year ago due to the impact of cancelled client trials. Revenue drops to GBP3.9 million from GBP4.9 million.

AIM WINNERS & LOSERS: SIMEC wins bumper deal; boohoo settles claim

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

UK earnings, trading statements calendar - next 7 days

Ixico joins Huntington's disease research consortium

(Sharecast News) - Neuroimaging contract research provider Ixico has entered a multi-party consortium for the early detection of Huntington's disease (HD), it announced on Tuesday.

TRADING UPDATES: CentralNic, Mind Gym anticipate growth in revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Ixico confident after first-half revenues fall

(Sharecast News) - Medical imaging technology company Ixico said in a trading update on Monday that it expected first-half revenues of £3.9m, down from £4.9m year-on-year.